•  
  •  
 

Abstract

Introduction. Antiretroviral therapy (ART) effectively suppress HIV replication. Viral load (VL) measurement is better predictor than clinical or immunological criteria to evaluate success or failure of ART. However, in country with limited resources, viral load measurement is not easily accessible by HIV patients receiving ART. Therefore, it is necessary to know which factors that can predict virological failure. In previous studies, adherence was an important factor for suppression of HIV viral load. This study is aimed to know predictors of virological failure in HIV patients receiving recent first line ART regimen with good adherence in Indonesia. Methods. A retrospective cohort study was conducted among adult HIV patients in Out-patient Clinic of Cipto Mangunkusumo Hospital that started ART during periode of January 2011-June 2014. HIV patients with good adherence that had viral load data 6-9 months after initiation of ART were included in this study. Virological failure was defined as viral load ≥ 400 copies/ mL after minimum of 6 months therapy with good adherence. Age at starting ART, risk factor for HIV infection, HIV clinical stage, HIV-TB co-infection, baseline CD4 value, CD4 count increase, baseline hemoglobin level and body mass index, weight changes during therapy, and ART based regimen were analyzed in this study. Results. A total of 197 patients were included in this study. Virological failure was found in 21 patients (10,7%). CD4 increase /mm3 after minimum 6 months of ART was predictor of virological failure (p = 0,003; OR 5,802, 95%CI 1,842-18,270). Conclusion. CD4 increase /mm3 after minimum 6 months therapy can predict virological failure in HIV patients receiving first line ART with good adherence

References

1. UNAIDS. Global report : UNAIDS report on global AIDS epidemic. Geneva: UNAIDS; 2013. p46-59. 2. World Health Organization (WHO). Global update on HIV treatment 2013: results, impact, and opportunities. Geneva: WHO; 2013. 3. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: WHO; 2013. 4. Tuboi SH, Harrison LH, Sprinz E, Albernaz RKM, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005;40(3):324–8. 5. Parienti JJ, Descamps D, Vabret A, Bouvet E, Larouze B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with Nevirapine or Efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;(39):1311–6. 6. Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet M, Ajayi S, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13:113. 7. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Wit TFR De, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya : a cross-sectional study. AIDS Res Ther. 2014;11(9):1–12. 8. Fibriani A, Wisaksana R, Indrati A, Hartantri Y, van de Vijver D, Schutten M, et al. Virological failure and drug resistance during first line anti-retroviral in Indonesia. J Med Virol. 2013;85:1394-401. 9. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Statistik Kasus HIV/AIDS di Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014. 10. Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8(1):42-9. 11. Meriki HD, Tufon K, Afegenwi MH, Nyindem B, Atanga PN, Anong DN, et al. Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon. Infect Dis Poverty. 2014;3(5):1-11. 12. Liu E, Spiegelman D, Semu H, Hawkins C, Chalamilla G, Aveika A, et al. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis. 2011;204(282):282–90. 13. Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Doran C, Zhang L. Determinants of virological failure after 1 year’s antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538-44. 14. Shearer K, Brennan AT, Maskew M, Long L, Berhanu R, Sanne I, et al. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014;17:19065. 15. Kusumaningrum A, Bela B, Ibrahim F, Yunihastuti E. Mutasi genetik dan resistensi obat HIV (HIVDR) pada pasien terinfeksi HIV-1 gagal terapi setelah mendapat enam bulan terapi antiretrovirus di RSUPN Ciptomangunkusumo periode September 2013–Maret 2014 [Tesis]. Jakarta: Universitas Indonesia; 2014. 16. Liegeois F, Vella C, Eymard-Duvernay S, Sica J, Makosso L, Mongo AD, et al. Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Intern AIDS Soc. 2012;15(17985):1-8. 17. Kumar RS. Immunovirological discordance in HIV. Medicine Update. 2012;22:89–93. 18. Zhou J, Sirisanthana T, Kiertiburanakul S, Chen Y-M a, Han N, Lim PL, et al. Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infect Dis. 2010;10:361-70. 19. Gilson R, Man SL, Copas A., Rider A., Forsyth S, Hill T, et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2010;11:152–60. 20. Bello EJM, Correia AF, Marins JRP, Merchan-Hamann E, Kanzaki LIB. Predictors of virologic failure in HIV/AIDS patients treated with highly active antiretroviral therapy in Brasília, Brazil during 2002- 2008. Drug Target Insights. 2011;5:33–41. 21. Database SHDR. Major HIV-1 Drug Resistance Mutations [Internet]. Stanford: Stanford Hiv Drug Resistance Database; 2013 [cited 2014 May 31]. Available from: http://hivdb.stanford.edu/ 22. Wensing AM, Calvez V, Günthard HF, Johnson V, Paredes R, Pillay D, et al. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22:642–50. 23. Labhardt ND, Lejone T, Setoko M, Poka M, Ehmer J, Pfeiffer K, et al. A clinical prediction score in addition to WHO criteria for antiretroviral treatment failure in resource-limited settings--experience from Lesotho. PLoS One. 2012;7(10):e47937. 24. Davies M-A, Boulle A, Eley B, Moultrie H, Technau K, Rabie H, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy-the IeDEA Southern Africa Collaboration. Trop Med Int Health. 2011;16(11):1367-71. 25. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health. 2009;14(10):1220–5. 26. Van Oosterhout JJG, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009;14(8):856–61. 27. Ferreyra C, Yun O, Eisenberg N, Alonso E, Khamadi AS, Mwau M, et al. Evaluation of clinical and immunological markers for predicting virological failure in a HIV/AIDS treatment cohort in Busia, Kenya. PLoS One. 2012;7(11):e49834. 28. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé J-L, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283–90. 29. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49(3):454–62. 30. Jourdain G, Le Cœur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, Fregonese F, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med. 2013;10(8):e1001494. 31. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8:89.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.